Patent ID: 7157444

Claim:
A therapeutic 5-aminosalicylic acid derivative composition having the general formula: wherein R is a reducing sugar that is selected from the group consisting of galactose, fucose, fructose, N-acetylglucosamine, N-acetylgalactosamine, maltobiose, lactobiose, cellobiose, and N,N-diacetylchitobiose, wherein a covalent bond to the oxygen of a hydroxyl group originally substituted on the reducing sugar has been replaced by a covalent bond to the nitrogen of the amino group of the 5-aminosalicylic acid derivative; a poly(ethylene glycol) chain-containing residue having the general formula —CH 2 CH 2 —CH 2 (CH 2 CH 2 O) n —R 1 , R 1 , is H or a linear or branched lower alkyl group having from one to about 6 carbons, and n is a positive integer from about 3 to about 100; or a poly(ethylene glycol) chain-containing tether having the general formula —CH 2 —(CH 2 CH 2 O) n —(CH 2 ) m -Z, in which n is a positive integer from about 3 to about 100, m is 2, 3, or 4, and Z is a drug or therapeutic agent having a molecular weight that is less than about 1000 Daltons that is covalently joined to the distal terminus of said poly(ethylene glycol) chain-containing tether.